Press Release
January 23, 2017

MagForce AG presents NanoTherm™ therapy for the treatment of brain tumors at ECCO2017 from January 27-30, 2017 in Amsterdam

The Company will also attend ESSO 37 One-Day Educational Conference held in conjunction with ECCO2017

Berlin, Germany and Nevada, USA, January 23rd, 2017 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today its attendance at ECCO2017, the European Cancer Congress held by the European CanCer Organisation (ECCO) from January 27-30, 2017, in Amsterdam, The Netherlands. The ECCO2017 Conference is an important meeting event for international key opinion leaders attending clinical symposia and sessions on multidisciplinary tumor boards focussing, amongst other indications, on the central nervous system.

This multidisciplinary oncology congress promotes close interaction between neurosurgeons, surgical oncologists and fellow oncology professionals.

At ECCO2017 congress, where new treatments of value to patients will be discussed and presented, MagForce will be represented by a booth (No. IH17) and will be available for questions regarding its NanoTherm™ therapy for the treatment of glioblastoma and other brain tumors.

About ECCO2017

ECCO2017 is a unique, clinically oriented, multidisciplinary annual congress with a strong educational focus for practicing oncologists and other health care professionals who need to be updated on the relevant clinical information which will impact on their daily practice. ECCO2017 is organized by European CanCer Organisation (ECCO) which, through its 25 Member Societies - representing over 80,000 professionals - is the only multidisciplinary organisation that connects and responds to all stakeholders in oncology Europe-wide.

The programme is built around the four key pillars multidisciplinarity, outcome research, health economics of cancer care and organisation of cancer care delivery.

ESSO 37 at ECCO2017

The European Society of Surgical Oncology invites all surgical oncologists and fellow oncology professionals from all disciplines to the ESSO society day at ECCO2017 on January 27th 2017.

Developed together with the Dutch Society for Surgical Oncology (NVCO), this one-day educational meeting will take place in conjunction with the European Cancer Congress (ECCO2017) to allow
the closest interaction between surgical oncologists and fellow oncology professionals.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list

For meeting arrangements or any further questions, please contact us at:

**Patient Advocacy**

Dr. Katarzyna Zarychta
+49 30 95 477 95-66
kzarychta@magforce.com

**Media & Investors**

Barbara von Frankenberg
+49 30 30 83 80-77
bfrankenberg@magforce.com

**Disclaimer**

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.